Pegaspargase - Servier
Alternative Names: Asparaginase macrogol; Lyophilised pegaspargase - Servier; Oncaspar; PEG-asparaginase; PEG-L-asparaginase; PEGLA; S 95014; SHP674Latest Information Update: 10 Mar 2023
At a glance
- Originator Enzon Pharmaceuticals
- Developer Enzon Pharmaceuticals; Leadiant Biosciences; Medac; Servier; Shire
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Acute myeloid leukaemia
Most Recent Events
- 23 Jan 2023 Servier completes a phase II trial in in pediatric patients with Acute lymphoblastic leukemia (ALL) in Russia (NCT04956666)
- 20 May 2022 Servier completes a phase II trials for Precursor cell lymphoblastic leukaemia-lymphoma (In children, in infants, In adolescents) in Russia (IV) (NCT04954326)
- 04 Feb 2022 Correct your HE - Servier completes a phase II trial in Precursor cell lymphoblastic leukaemia-lymphoma (Newly diagnosed, First-line therapy, In infants, In childrens, In adolescents, In adults) in Japan (IV) (NCT04067518)